Myocardial glycogen dynamics: New perspectives on disease mechanisms

Clinical and Experimental Pharmacology and Physiology

Volumn 42, Issue 4, 2015, Pages 415-425

  Chandramouli, Chanchal ^a   Varma, Upasna ^a   Stevens, Ellie M ^b   Xiao, Rui Ping ^c   Stapleton, David I ^a,d   Mellor, Kimberley M ^a,b   Delbridge, Lea M D ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b UNIVERSITY OF AUCKLAND   (New Zealand)

^c PEKING UNIVERSITY   (China)

^d FLOREY INSTITUTE OF NEUROSCIENCE AND MENTAL HEALTH   (Australia)

Author keywords

Autophagy; Cardiac; Glucose; Glycogen storage diseases; Glycophagy; Heart; Metabolic stress

Indexed keywords

ALPHA GLUCOSIDASE; GLUCAN 1,4 ALPHA GLUCOSIDASE; GLYCOGEN; GLYCOGEN DEBRANCHING ENZYME; GLYCOGEN PHOSPHORYLASE; INSULIN; LYSOSOME ASSOCIATED MEMBRANE PROTEIN 2;

ARTICLE; AUTOPHAGOSOME; AUTOPHAGY; CELLULAR DISTRIBUTION; ENZYME ACTIVE SITE; ENZYME SYNTHESIS; GLYCOGEN ANALYSIS; GLYCOGEN METABOLISM; GLYCOGEN STORAGE DISEASE; GLYCOGEN SYNTHESIS; HEART MUSCLE; HUMAN; IMMUNOLOCALIZATION; METABOLIC STRESS; MUSCLE CONTRACTION; NONHUMAN; PROTEIN EXPRESSION; PROTEIN FUNCTION; ANIMAL; ENERGY METABOLISM; HEART DISEASE; KINETICS; LYSOSOME; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; PHAGOSOME; SIGNAL TRANSDUCTION;

ANIMALS; ENERGY METABOLISM; GLYCOGEN; GLYCOGEN STORAGE DISEASE; HEART DISEASES; HUMANS; KINETICS; LYSOSOMES; MYOCARDIUM; PHAGOSOMES; SIGNAL TRANSDUCTION;

EID: 84925457539     PISSN: 03051870     EISSN: 14401681     Source Type: Journal    
DOI: 10.1111/1440-1681.12370     Document Type: Article

References (134)

1. Dudley HW, Marrian GF. The effect of insulin on the glycogen in the tissues of normal animals. Biochem. J. 1923; 17: 435-8.
2. Evans G. The glycogen content of the rat heart. J. Physiol. 1934; 82: 468-80.
3. Visscher MB, Mulder AG. The carbohydrate metabolism of the heart. Am. J. Physiol. 1930; 94: 630-40.
4. Rabinowitz M. Control of metabolism and synthesis of macromolecules in normal and ischemic heart. J. Mol. Cell. Cardiol. 1971; 2: 277-92.
5. Shin YS. Glycogen storage disease: Clinical, biochemical, and molecular heterogeneity. Semin. Pediatr. Neurol. 2006; 13: 115-20.
6. Hicks J, Wartchow E, Mierau G. Glycogen storage diseases: A brief review and update on clinical features, genetic abnormalities, pathologic features, and treatment. Ultrastruct. Pathol. 2011; 35: 183-96.
7. Liu KM, Wu JY, Chen YT. Mouse model of glycogen storage disease type III. Mol. Genet. Metab. 2014; 111: 467-76.
8. Pagliarani S, Lucchiari S, Ulzi G et al. Glycogen storage disease type III: A novel Agl knockout mouse model. Biochim. Biophys. Acta 2014; 1842: 2318-28.
9. Garyali P, Segvich DM, DePaoli-Roach AA, Roach PJ. Protein degradation and quality control in cells from laforin and malin knockout mice. J. Biol. Chem. 2014; 289: 20606-14.
10. Reichelt ME, Mellor KM, Curl CL, Stapleton D, Delbridge LM. Myocardial glycophagy - A specific glycogen handling response to metabolic stress is accentuated in the female heart. J. Mol. Cell. Cardiol. 2013; 65: 67-75.
11. Mellor KM, Varma U, Stapleton D, Delbridge LMD. Cardiomyocyte glycophagy is regulated by insulin and exposure to high extracellular glucose. Am. J. Physiol. Heart Circ. Physiol. 2014; 306: H1240-5.
12. Jiang S, Wells CD, Roach PJ. Starch-binding domain-containing protein 1 (Stbd1) and glycogen metabolism: Identification of the Atg8 family interacting motif (AIM) in Stbd1 required for interaction with GABARAPL1. Biochem. Biophys. Res. Commun. 2011; 413: 420-5.
13. Larner J, Illingworth B, Cori GT, Cori CF. Structure of glycogens and amylopectins. II. Analysis by stepwise enzymatic degradation. J. Biol. Chem. 1952; 199: 641-51.
14. Meyer KH, Bernfeld P, Boissonnas RA, Gurtler P, Noelting G. Starch solutions and pastes and their molecular interpretation. J. Phys. Colloid Chem. 1949; 53: 319.
15. Ryu JH, Drain J, Kim JH et al. Comparative structural analyses of purified glycogen particles from rat liver, human skeletal muscle and commercial preparations. Int. J. Biol. Macromol. 2009; 45: 478-82.
16. Drochmans P. Morphologie du glycogène: Etude au microscope électronique de colorations négatives du glycogène particulaire. J. Ultrastruct. Res. 1962; 6: 141-63.
17. Marchand I, Chorneyko K, Tarnopolsky M et al. Quantification of subcellular glycogen in resting human muscle: Granule size, number, and location. J. Appl. Physiol. (1985) 2002; 93: 1598-607.
18. Besford QA, Sullivan MA, Zheng L, Gilbert RG, Stapleton D, Gray-Weale A. The structure of cardiac glycogen in healthy mice. Int. J. Biol. Macromol. 2012; 51: 887-91.
19. Depre C, Vanoverschelde JL, Taegtmeyer H. Glucose for the heart. Circulation 1999; 99: 578-88.
20. Pederson BA, Chen H, Schroeder JM, Shou W, DePaoli-Roach AA, Roach PJ. Abnormal cardiac development in the absence of heart glycogen. Mol. Cell. Biol. 2004; 24: 7179-87.
21. Alfarano C, Suffredini S, Fantappie O et al. The effect of losartan treatment on the response of diabetic cardiomyocytes to ATP depletion. Pharmacol. Res. 2011; 63: 225-32.
22. Graham TE, Yuan Z, Hill AK, Wilson RJ. The regulation of muscle glycogen: The granule and its proteins. Acta Physiol. (Oxf.) 2010; 199: 489-98.
23. Entman ML, Bornet EP, Van Winkle WB, Goldstein MA, Schwartz A. Association of glycogenolysis with cardiac sarcoplasmic reticulum: II. Effect of glycogen depletion, deoxycholate solubilization and cardiac ischemia: Evidence for a phorphorylase kinase membrane complex. J. Mol. Cell. Cardiol. 1977; 9: 515-28.
24. Rybicka K. Binding of glycosomes to endoplasmic reticulum and to intermediate filaments in cardiac conduction fibers. J. Histochem. Cytochem. 1981; 29: 553-60.
25. Pierce GN, Philipson KD. Binding of glycolytic enzymes to cardiac sarcolemmal and sarcoplasmic reticular membranes. J. Biol. Chem. 1985; 260: 6862-70.
26. 2+ release by glycolysis in cat atrial myocytes. J. Physiol. 2005; 564: 697-714.
27. Laks MM, Van de Velde S, Swan HJ. The presence and location of glycogen in the hypertrophied right ventricle of the canine heart. Cardiovasc. Res. 1969; 3: 272-6.
28. Nielsen J, Schroder HD, Rix CG, Ortenblad N. Distinct effects of subcellular glycogen localization on tetanic relaxation time and endurance in mechanically skinned rat skeletal muscle fibres. J. Physiol. 2009; 587: 3679-90.
29. 2+ kinetics in human skeletal muscle. J. Physiol. 2011; 589: 711-25.
30. Kondomerkos DJ, Kalamidas SA, Kotoulas OB, Hann AC. Glycogen autophagy in the liver and heart of newborn rats. The effects of glucagon, adrenalin or rapamycin. Histol. Histopathol. 2005; 20: 689-96.
31. Kondomerkos DJ, Kalamidas SA, Kotoulas OB. An electron microscopic and biochemical study of the effects of glucagon on glycogen autophagy in the liver and heart of newborn rats. Microsc. Res. Tech. 2004; 63: 87-93.
32. Fayssoil A. Cardiomyopathy in Pompe's disease. Eur. J. Intern. Med. 2008; 19: 57-9.
33. Anousis N, Carvalho RA, Zhao P, Malloy CR, Sherry AD. Compartmentation of glycolysis and glycogenolysis in the perfused rat heart. NMR Biomed. 2004; 17: 51-9.
34. Roach PJ, Skurat AV. Self-glucosylating initiator proteins and their role in glycogen biosynthesis. Prog. Nucleic Acid Res. Mol. Biol. 1997; 57: 289-316.
35. Roach PJ, Depaoli-Roach AA, Hurley TD, Tagliabracci VS. Glycogen and its metabolism: Some new developments and old themes. Biochem. J. 2012; 441: 763-87.
36. Nase S, Kunze KP, Sigmund M, Schroeder JM, Shin Y, Hanrath P. A new variant of type IV glycogenosis with primary cardiac manifestation and complete branching enzyme deficiency. In vivo detection by heart muscle biopsy. Eur. Heart J. 1995; 16: 1698-704.
37. Shen JJ, Chen YT. Molecular characterization of glycogen storage disease type III. Curr. Mol. Med. 2002; 2: 167-75.
38. Stapleton D, Nelson C, Parsawar K et al. Analysis of hepatic glycogen-associated proteins. Proteomics 2010; 10: 2320-9.
39. Tagliabracci VS, Heiss C, Karthik C et al. Phosphate incorporation during glycogen synthesis and Lafora disease. Cell Metab. 2011; 13: 274-82.
40. Nitschke F, Wang P, Schmieder P et al. Hyperphosphorylation of glucosyl C6 carbons and altered structure of glycogen in the neurodegenerative epilepsy Lafora disease. Cell Metab. 2013; 17: 756-67.
41. Tagliabracci VS, Turnbull J, Wang W et al. Laforin is a glycogen phosphatase, deficiency of which leads to elevated phosphorylation of glycogen in vivo. Proc. Natl Acad. Sci. USA 2007; 104: 19262-6.
42. Tagliabracci VS, Girard JM, Segvich D et al. Abnormal metabolism of glycogen phosphate as a cause for Lafora disease. J. Biol. Chem. 2008; 283: 33 816-25.
43. Jiang S, Heller B, Tagliabracci VS et al. Starch binding domain-containing protein 1/genethonin 1 is a novel participant in glycogen metabolism. J. Biol. Chem. 2010; 285: 34 960-71.
44. Zhu Y, Zhang M, Kelly AR, Cheng A. The carbohydrate-binding domain of overexpressed STBD1 is important for its stability and protein-protein interactions. Biosci. Rep. 2014; 34: 311-320.
45. Onodera S, Matsui H, Chiba S. Substrate specificity and subsite affinities of rabbit liver acid alpha-glucosidase. J. Biochem. 1994; 116: 7-11.
46. Palmer TN. The substrate specificity of acid-glucosidase from rabbit muscle. Biochem. J. 1971; 124: 701-11.
47. Tashiro K, Iwamasa T, Kato H, Ogata S, Anai M. Purification and characterization of two components of acid alpha-glucosidase from pig liver. J. Biochem. 1986; 99: 693-701.
48. Chambers JP, Williams JC. Acid alpha-glucosidase from human heart. Enzyme 1983; 29: 109-19.
49. Kandel ES, Hay N. The regulation and activities of the multifunctional serine/threonine kinase Akt/PKB. Exp. Cell Res. 1999; 253: 210-29.
50. Goodwin GW, Arteaga JR, Taegtmeyer H. Glycogen turnover in the isolated working rat heart. J. Biol. Chem. 1995; 270: 9234-40.
51. Cohen P. The Croonian Lecture 1998. Identification of a protein kinase cascade of major importance in insulin signal transduction. Philos. Trans. R. Soc. Lond. B Biol. Sci. 1999; 354: 485-95.
52. Mora A, Sakamoto K, McManus EJ, Alessi DR. Role of the PDK1-PKB-GSK3 pathway in regulating glycogen synthase and glucose uptake in the heart. FEBS Lett. 2005; 579: 3632-8.
53. Wang L, Wang X, Proud CG. Activation of mRNA translation in rat cardiac myocytes by insulin involves multiple rapamycin-sensitive steps. Am. J. Physiol. Heart Circ. Physiol. 2000; 278: H1056-68.
54. Wolleben CD, Jaspers SR, Miller TB Jr. Use of adult rat cardiomyocytes to study cardiac glycogen metabolism. Am. J. Physiol. 1987; 252: E673-8.
55. De Luca JP, Garnache AK, Rulfs J, Miller TB Jr. Wortmannin inhibits insulin-stimulated activation of protein phosphatase 1 in rat cardiomyocytes. Am. J. Physiol. 1999; 276: H1520-6.
56. Crosson SM, Khan A, Printen J, Pessin JE, Saltiel AR. PTG gene deletion causes impaired glycogen synthesis and developmental insulin resistance. J. Clin. Invest. 2003; 111: 1423-32.
57. Brady MJ, Printen JA, Mastick CC, Saltiel AR. Role of protein targeting to glycogen (PTG) in the regulation of protein phosphatase-1 activity. J. Biol. Chem. 1997; 272: 20198-204.
58. Bouskila M, Hunter RW, Ibrahim AF et al. Allosteric regulation of glycogen synthase controls glycogen synthesis in muscle. Cell Metab. 2010; 12: 456-66.
59. McNeel RL, Mersmann HJ. Distribution and quantification of beta1-, beta2-, and beta3-adrenergic receptor subtype transcripts in porcine tissues. J. Anim. Sci. 1999; 77: 611-21.
60. Woo AY, Xiao RP. beta-Adrenergic receptor subtype signaling in heart: From bench to bedside. Acta Pharmacol. Sin. 2012; 33: 335-41.
61. Xiao RP, Zhang SJ, Chakir K et al. Enhanced G(i) signaling selectively negates beta2-adrenergic receptor (AR)-but not beta1-AR-mediated positive inotropic effect in myocytes from failing rat hearts. Circulation 2003; 108: 1633-9.
62. Kuschel M, Zhou YY, Spurgeon HA et al. beta2-adrenergic cAMP signaling is uncoupled from phosphorylation of cytoplasmic proteins in canine heart. Circulation 1999; 99: 2458-65.
63. McConville P, Lakatta EG, Spencer RG. Greater glycogen utilization during 1- than 2-adrenergic receptor stimulation in the isolated perfused rat heart. Am. J. Physiol. Endocrinol. Metab. 2007; 293: E1828-35.
64. Neumann J, Gupta RC, Schmitz W, Scholz H, Nairn AC, Watanabe AM. Evidence for isoproterenol-induced phosphorylation of phosphatase inhibitor-1 in the intact heart. Circ. Res. 1991; 69: 1450-7.
65. Gupta RC, Neumann J, Watanabe AM, Sabbah HN. Inhibition of type 1 protein phosphatase activity by activation of beta-adrenoceptors in ventricular myocardium. Biochem. Pharmacol. 2002; 63: 1069-76.
66. Carling D. The AMP-activated protein kinase cascade-a unifying system for energy control. Trends Biochem. Sci. 2004; 29: 18-24.
67. Gollob MH. Glycogen storage disease as a unifying mechanism of disease in the PRKAG2 cardiac syndrome. Biochem. Soc. Trans. 2003; 31: 228-31.
68. Dyck JR, Lopaschuk GD. AMPK alterations in cardiac physiology and pathology: Enemy or ally? J. Physiol. 2006; 574: 95-112.
69. Murphy RT, Mogensen J, McGarry K et al. Adenosine monophosphate-activated protein kinase disease mimicks hypertrophic cardiomyopathy and Wolff-Parkinson-White syndrome: Natural history. J. Am. Coll. Cardiol. 2005; 45: 922-30.
70. Arad M, Moskowitz IP, Patel VV et al. Transgenic mice overexpressing mutant PRKAG2 define the cause of Wolff-Parkinson-White syndrome in glycogen storage cardiomyopathy. Circulation 2003; 107: 2850-6.
71. Carling D, Hardie DG. The substrate and sequence specificity of the AMP-activated protein kinase. Phosphorylation of glycogen synthase and phosphorylase kinase. Biochim. Biophys. Acta 1989; 1012: 81-6.
72. Wojtaszewski JF, Jorgensen SB, Hellsten Y, Hardie DG, Richter EA. Glycogen-dependent effects of 5-aminoimidazole-4-carboxamide (AICA)-riboside on AMP-activated protein kinase and glycogen synthase activities in rat skeletal muscle. Diabetes 2002; 51: 284-92.
73. Beyer A, Kitzerow A, Crute B, Kemp BE, Witters LA, Heilmeyer LM Jr. Muscle phosphorylase kinase is not a substrate of AMP-activated protein kinase. Biol. Chem. 2000; 381: 457-61.
74. Hunter RW, Treebak JT, Wojtaszewski JF, Sakamoto K. Molecular mechanism by which AMP-activated protein kinase activation promotes glycogen accumulation in muscle. Diabetes 2011; 60: 766-74.
75. Banerjee SK, Wang DW, Alzamora R et al. SGLT1, a novel cardiac glucose transporter, mediates increased glucose uptake in PRKAG2 cardiomyopathy. J. Mol. Cell. Cardiol. 2010; 49: 683-92.
76. Polekhina G, Gupta A, Michell BJ et al. AMPK beta subunit targets metabolic stress sensing to glycogen. Curr. Biol. 2003; 13: 867-71.
77. Polekhina G, Gupta A, van Denderen BJ et al. Structural basis for glycogen recognition by AMP-activated protein kinase. Structure 2005; 13: 1453-62.
78. Hudson ER, Pan DA, James J et al. A novel domain in AMP-activated protein kinase causes glycogen storage bodies similar to those seen in hereditary cardiac arrhythmias. Curr. Biol. 2003; 13: 861-6.
79. Banerjee SK, Ramani R, Saba S et al. A PRKAG2 mutation causes biphasic changes in myocardial AMPK activity and does not protect against ischemia. Biochem. Biophys. Res. Commun. 2007; 360: 381-7.
80. Ahmad F, Arad M, Musi N et al. Increased alpha2 subunit-associated AMPK activity and PRKAG2 cardiomyopathy. Circulation 2005; 112: 3140-8.
81. Ofir M, Arad M, Porat E et al. Increased glycogen stores due to gamma-AMPK overexpression protects against ischemia and reperfusion damage. Biochem. Pharmacol. 2008; 75: 1482-91.
82. Luptak I, Shen M, He H et al. Aberrant activation of AMP-activated protein kinase remodels metabolic network in favor of cardiac glycogen storage. J. Clin. Invest. 2007; 117: 1432-9.
83. Puthanveetil P, Wang F, Kewalramani G et al. Cardiac glycogen accumulation after dexamethasone is regulated by AMPK. Am. J. Physiol. Heart Circ. Physiol. 2008; 295: H1753-62.
84. Longnus SL, Wambolt RB, Parsons HL, Brownsey RW, Allard MF. 5-Aminoimidazole-4-carboxamide 1-beta-d-ribofuranoside (AICAR) stimulates myocardial glycogenolysis by allosteric mechanisms. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2003; 284: R936-44.
85. Aschenbach WG, Hirshman MF, Fujii N, Sakamoto K, Howlett KF, Goodyear LJ. Effect of AICAR treatment on glycogen metabolism in skeletal muscle. Diabetes 2002; 51: 567-73.
86. Holmes BF, Kurth-Kraczek EJ, Winder WW. Chronic activation of 5′-AMP-activated protein kinase increases GLUT-4, hexokinase, and glycogen in muscle. J. Appl. Physiol. (1985) 1999; 87: 1990-5.
87. Russell RR 3rd, Bergeron R, Shulman GI, Young LH. Translocation of myocardial GLUT-4 and increased glucose uptake through activation of AMPK by AICAR. Am. J. Physiol. 1999; 277: H643-9.
88. Kristiansen SB, Solskov L, Jessen N et al. 5-Aminoimidazole-4-carboxamide-1-beta-d-ribofuranoside increases myocardial glucose uptake during reperfusion and induces late pre-conditioning: Potential role of AMP-activated protein kinase. Basic Clin. Pharmacol. Toxicol. 2009; 105: 10-6.
89. Chopra I, Li HF, Wang H, Webster KA. Phosphorylation of the insulin receptor by AMP-activated protein kinase (AMPK) promotes ligand-independent activation of the insulin signalling pathway in rodent muscle. Diabetologia 2012; 55: 783-94.
90. Di Sant'Agnese PA, Andersen DH, Mason HH. Glycogen storage disease of the heart. II. Critical review of the literature. Pediatrics 1950; 6: 607-24.
91. Chen M. Glycogen storage diseases. In: Monga SPS (ed.). Molecular Pathology of Liver Diseases. Springer, Boston. 2011; Ch. 45.
92. Moses SW. Historical highlights and unsolved problems in glycogen storage disease type 1. Eur. J. Pediatr. 2002; 161(Suppl. 1): S2-9.
93. Nordlie RC, Sukalski KA, Munoz JM, Baldwin JJ. Type Ic, a novel glycogenosis. Underlying mechanism. J. Biol. Chem. 1983; 258: 9739-44.
94. Wolfsdorf JI, Weinstein DA. Glycogen storage diseases. Rev. Endocr. Metab. Disord. 2003; 4: 95-102.
95. Lim JA, Li L, Raben N. Pompe disease: From pathophysiology to therapy and back again. Front. Aging Neurosci. 2014; 6: 177.
96. Kishnani PS, Hwu WL, Mandel H et al. A retrospective, multinational, multicenter study on the natural history of infantile-onset Pompe disease. J. Pediatr. 2006; 148: 671-6.
97. Fernandez C, Legido A, Jethva R, Marks HG. Correction of a short cardiac PR interval in a 12-year-old girl with late-onset Pompe disease following enzyme replacement therapy. Genet. Med. 2012; 14: 757-8.
98. Van den Hout JM, Kamphoven JH, Winkel LP et al. Long-term intravenous treatment of Pompe disease with recombinant human alpha-glucosidase from milk. Pediatrics 2004; 113: e448-57.
99. Fayssoil A, Nardi O, Annane D, Orlikowski D. Right ventricular function in late-onset Pompe disease. J. Clin. Monit. Comput. 2014; 28: 419-21.
100. Bulkley BH, Hutchins GM. Pompe's disease presenting as hypertrophic myocardiopathy with Wolff-Parkinson-White syndrome. Am. Heart J. 1978; 96: 246-52.
101. Francesconi M, Auff E. Cardiac arrhythmias and the adult form of type II glycogenosis. N. Engl. J. Med. 1982; 306: 937-8.
102. Raben N, Nagaraju K, Lee E et al. Targeted disruption of the acid alpha-glucosidase gene in mice causes an illness with critical features of both infantile and adult human glycogen storage disease type II. J. Biol. Chem. 1998; 273: 19 086-92.
103. Mah C, Pacak CA, Cresawn KO et al. Physiological correction of Pompe disease by systemic delivery of adeno-associated virus serotype 1 vectors. Mol. Ther. 2007; 15: 501-7.
104. Xu F, Ding E, Migone F et al. Glycogen storage in multiple muscles of old GSD-II mice can be rapidly cleared after a single intravenous injection with a modified adenoviral vector expressing hGAA. J. Gene Med. 2005; 7: 171-8.
105. Zhu Y, Jiang JL, Gumlaw NK et al. Glycoengineered acid alpha-glucosidase with improved efficacy at correcting the metabolic aberrations and motor function deficits in a mouse model of Pompe disease. Mol. Ther. 2009; 17: 954-63.
106. Farah BL, Madden L, Li S et al. Adjunctive beta2-agonist treatment reduces glycogen independently of receptor-mediated acid alpha-glucosidase uptake in the limb muscles of mice with Pompe disease. FASEB J. 2014; 28: 2272-80.
107. Khanna R, Flanagan JJ, Feng J et al. The pharmacological chaperone AT2220 increases recombinant human acid alpha-glucosidase uptake and glycogen reduction in a mouse model of Pompe disease. PLoS ONE 2012; 7: e40776.
108. Ashe KM, Taylor KM, Chu Q et al. Inhibition of glycogen biosynthesis via mTORC1 suppression as an adjunct therapy for Pompe disease. Mol. Genet. Metab. 2010; 100: 309-15.
109. Danon MJ, Oh SJ, DiMauro S et al. Lysosomal glycogen storage disease with normal acid maltase. Neurology 1981; 31: 51-7.
110. Nishino I, Fu J, Tanji K et al. Primary LAMP-2 deficiency causes X-linked vacuolar cardiomyopathy and myopathy (Danon disease). Nature 2000; 406: 906-10.
111. Charron P, Villard E, Sebillon P et al. Danon's disease as a cause of hypertrophic cardiomyopathy: A systematic survey. Heart 2004; 90: 842-6.
112. Bui YK, Renella P, Martinez-Agosto JA, Verity A, Madikians A, Alejos JC. Danon disease with typical early-onset cardiomyopathy in a male: Focus on a novel LAMP-2 mutation. Pediatr. Transplant. 2008; 12: 246-50.
113. Boucek D, Jirikowic J, Taylor M. Natural history of Danon disease. Genet. Med. 2011; 13: 563-8.
114. Yang Z, Vatta M. Danon disease as a cause of autophagic vacuolar myopathy. Congenit. Heart. Dis. 2007; 2: 404-9.
115. Nishino I. Autophagic vacuolar myopathies. Curr. Neurol. Neurosci. Rep. 2003; 3: 64-9.
116. Arad M, Maron BJ, Gorham JM et al. Glycogen storage diseases presenting as hypertrophic cardiomyopathy. N. Engl. J. Med. 2005; 352: 362-72.
117. Stypmann J, Janssen PM, Prestle J et al. LAMP-2 deficient mice show depressed cardiac contractile function without significant changes in calcium handling. Basic Res. Cardiol. 2006; 101: 281-91.
118. Tanaka Y, Guhde G, Suter A et al. Accumulation of autophagic vacuoles and cardiomyopathy in LAMP-2-deficient mice. Nature 2000; 406: 902-6.
119. Eskelinen EL, Illert AL, Tanaka Y et al. Role of LAMP-2 in lysosome biogenesis and autophagy. Mol. Biol. Cell 2002; 13: 3355-68.
120. Austin SL, Proia AD, Spencer-Manzon MJ, Butany J, Wechsler SB, Kishnani PS. Cardiac pathology in glycogen storage disease type III. JIMD Rep. 2012; 6: 65-72.
121. Olson LJ, Reeder GS, Noller KL, Edwards WD, Howell RR, Michels VV. Cardiac involvement in glycogen storage disease III: Morphologic and biochemical characterization with endomyocardial biopsy. Am. J. Cardiol. 1984; 53: 980-1.
122. Yi H, Brooks ED, Thurberg BL, Fyfe JC, Kishnani PS, Sun B. Correction of glycogen storage disease type III with rapamycin in a canine model. J. Mol. Med. (Berl.) 2014; 92: 641-50.
123. Sun B, Fredrickson K, Austin S et al. Alglucosidase alfa enzyme replacement therapy as a therapeutic approach for glycogen storage disease type III. Mol. Genet. Metab. 2013; 108: 145-7.
124. Yi H, Thurberg BL, Curtis S et al. Characterization of a canine model of glycogen storage disease type IIIa. Dis. Model Mech. 2012; 5: 804-11.
125. Cheng A, Zhang M, Okubo M, Omichi K, Saltiel AR. Distinct mutations in the glycogen debranching enzyme found in glycogen storage disease type III lead to impairment in diverse cellular functions. Hum. Mol. Genet. 2009; 18: 2045-52.
126. Cheng A, Zhang M, Gentry MS, Worby CA, Dixon JE, Saltiel AR. A role for AGL ubiquitination in the glycogen storage disorders of Lafora and Cori's disease. Genes Dev. 2007; 21: 2399-409.
127. Ganesh S, Agarwala KL, Ueda K et al. Laforin, defective in the progressive myoclonus epilepsy of Lafora type, is a dual-specificity phosphatase associated with polyribosomes. Hum. Mol. Genet. 2000; 9: 2251-61.
128. Gentry MS, Worby CA, Dixon JE. Insights into Lafora disease: Malin is an E3 ubiquitin ligase that ubiquitinates and promotes the degradation of laforin. Proc. Natl Acad. Sci. USA 2005; 102: 8501-6.
129. Lohi H, Ianzano L, Zhao XC et al. Novel glycogen synthase kinase 3 and ubiquitination pathways in progressive myoclonus epilepsy. Hum. Mol. Genet. 2005; 14: 2727-36.
130. Worby CA, Gentry MS, Dixon JE. Malin decreases glycogen accumulation by promoting the degradation of protein targeting to glycogen (PTG). J. Biol. Chem. 2008; 283: 4069-76.
131. Acharya JN, Satishchandra P, Asha T, Shankar SK. Lafora's disease in south India: A clinical, electrophysiologic, and pathologic study. Epilepsia 1993; 34: 476-87.
132. DePaoli-Roach AA, Tagliabracci VS, Segvich DM, Meyer CM, Irimia JM, Roach PJ. Genetic depletion of the malin E3 ubiquitin ligase in mice leads to lafora bodies and the accumulation of insoluble laforin. J. Biol. Chem. 2010; 285: 25 372-81.
133. Vernia S, Heredia M, Criado O et al. Laforin, a dual specificity phosphatase involved in Lafora disease, regulates insulin response and whole-body energy balance in mice. Hum. Mol. Genet. 2011; 20: 2571-84.
134. DePaoli-Roach AA, Segvich DM, Meyer CM et al. Laforin and malin knockout mice have normal glucose disposal and insulin sensitivity. Hum. Mol. Genet. 2012; 21: 1604-10.